Savient Announces Multiple Abstracts Related to KRYSTEXXA
Savient Pharmaceuticals (Nasdaq: SVNT) today announced that several abstracts related to KRYSTEXXA® (pegloticase) in the treatment of patients with Refractory Chronic Gout (RCG) will be presented at the 2012 ACR/ARHP Annual Meeting taking place in Washington D.C., from November 9-14, 2012.
Full text of the following accepted abstracts can be accessed by visiting the American College of Rheumatology website at www.rheumatology.org.
Complete Tophus Response in Patients with Chronic Gout Initiating Pegloticase Treatment; Abstract #1913 Clinical Efficacy Outcomes with Up to 3 Years of Pegloticase Treatment for Refractory Chronic Gout; Abstract #159 Improvements in Long-Term Health-Related Quality of Life in Chronic Gout Patients Refractory to Conventional Therapies Treated with Pegloticase: Results from Responder Cohort; Abstract #147 Patterns of Gout Treatment and Related Outcomes in US Community Rheumatology Practices: the Relation Between Gout Flares, Time in Treatment, Serum Uric Acid Level and Urate Lowering Therapy; Abstract #1904 Pegloticase Long Term Safety: Data from the Open Label Extension Trial; Abstract #160 Post‐Marketing Safety Surveillance Data Reveals Patterns of Use for Pegloticase in Refractory Chronic Gout; Abstract #169 Relative Risk of Infusion Reactions with KRYSTEXXA® (pegloticase) from Post-Approval Safety Data: Results from Sept 2010 to June 2012; Abstract #170 Serum Uric Acid as a Biomarker for Mitigation of Infusion Reactions in Patients Treated with Pegloticase for Refractory Chronic Gout; Abstract #1916
(c) 2013 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.